Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBPP) Return on Capital Employed (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Return on Capital Employed for 12 consecutive years, with 0.05% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 3.0% to 0.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.05%, a 3.0% decrease, with the full-year FY2025 number at 0.05%, down 3.0% from a year prior.
  • Return on Capital Employed was 0.05% for Q3 2025 at Regen BioPharma, up from 0.05% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.15% in Q2 2023 to a low of 0.0% in Q1 2022.
  • A 5-year average of 0.07% and a median of 0.06% in 2024 define the central range for Return on Capital Employed.
  • Biggest YoY gain for Return on Capital Employed was 14bps in 2023; the steepest drop was -8bps in 2023.
  • Regen BioPharma's Return on Capital Employed stood at 0.03% in 2021, then skyrocketed by 377bps to 0.14% in 2022, then crashed by -52bps to 0.07% in 2023, then decreased by -10bps to 0.06% in 2024, then fell by -14bps to 0.05% in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Return on Capital Employed are 0.05% (Q3 2025), 0.05% (Q2 2025), and 0.06% (Q1 2025).